ALK-positive primary systemic anaplastic large cell lymphoma with extensive cutaneous manifestation

Acta Dermato-Venereologica

Volumn 90, Issue 2, 2010, Pages 198-200

  Ando, Kazuha ^a   Tamada, Yasuhiko ^a   Shimizu, Kazuyuki ^b   Akita, Yoichi ^a   Watanabe, Daisuke ^a   Nakamura, Shigeru ^b   Hara, Kazuo ^a   Matsumoto, Yoshinari ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GAMMA INTERFERON; LARGE CELL LYMPHOMA KINASE; MERCAPTOPURINE; METHOTREXATE; PHOSPHOTRANSFERASE; PREDNISOLONE; PROCARBAZINE; PSORALEN; UNCLASSIFIED DRUG; VINCRISTINE;

ABDOMINAL PAIN; ADULT; CANCER RECURRENCE; CASE REPORT; DIARRHEA; ERYTHEMA; FEMALE; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LETTER; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PUVA; RASH; RECURRENT CANCER; SKIN INDURATION; SKIN LYMPHOMA; TREATMENT REFUSAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; PHOTOCHEMOTHERAPY; PROTEIN-TYROSINE KINASES; RECURRENCE; SKIN; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950271005     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0775     Document Type: Letter

References (11)

1. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, et al. The expression of the Hodgkin disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848-858.
2. Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000; 96: 3681-3695.
3. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, et al. Anaplastic large cell lymphomas expressing the chimeric protein p80 NPM/ALK: a distinct clinico-pathologic entity. Blood 1995; 86: 1954-1960.
4. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913-3921.
5. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
6. Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, et al. Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-3661.
7. Mencía-Gutiérrez E, Gutiérrez-Díaz E, Salamanca J, Martínez-González MA. Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase(ALK)-negative, anaplastic large cell lymphoma(ALCL). Int J Derm 2006; 45: 766-769.
8. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697-2706.
9. Brugières L, Deley MC, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A, et al. CD30+ Anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 1998; 92: 3591-3598.
10. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007; 110: 2259-2267.
11. Brugières L, Quartier P, Le Deley MC, Pacquement H, Perel Y, Bergeron C, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children - a report from the French Society of Pediatric Oncology. Ann Oncol 2000; 11: 53-58.